Konferensiyani muvaffaqiyatli tamomlagandan so'ng Yusufjon Gafforov aka bilan bozorlarni aylandik. Kerakli harajatlarni qilib, sobiq hamkasbimiz Quan-Zhi Zhang taklifiga asosan birga kechki ovqat tanovul qildik. Suhbat rosa qizidi. Hammasi uchun Sizlarga katta Rahmat Akbarjon Ro'zimov, Yusufjon aka va Quan-Zhi. Vatanga qaytish vaqti keldi. Hamkorlarimiz bilan ishlarimiz rejadagiday natijalar bersa nasib yana Pekinga kelamiz albatta.

Dear colleagues,
Our GEC-IOPS (International Online Plasma Seminar) presentation is scheduled as follows
Date & Time: 4 Jul 2024 at 1:00 pm UTC
Title: Generating Atomic Data for Plasma Physics on the AMOS Gateway
Speaker: Kathryn Hamilton
University of Colorado Denver

---------------------

Title: Unraveling Nonequilibrium Generation of Atomic Nitrogen and Hydrogen in Plasma-Aided Ammonia Synthesis
Speaker: Ning Liu
City University of Hong Kong
Category: Research Highlight
​
​IOPS seminar.ics​

To join the seminar, please use the following link:
​https://us06web.zoom.us/j/86909230871?pwd=czNsUDVIL2FtWVRjWmpDYWRrUktYUT09​
Meeting ID: 869 0923 0871
Passcode: jC77pbWS

CHARMM-GUI Multicomponent Assembler for modeling and simulation of complex multicomponent systems https://www.nature.com/articles/s41467-024-49700-4

Dresden University of Technology invites application for vacant (92) PhD, Postdoc and Research Positions
https://scholaridea.com/2024/06/29/dresden-university-of-technology-invites-application-for-vacant-92-phd-postdoc-and-research-positions/

Can fortified drinks and spreads really reduce cholesterol?

Almost half of UK adults have raised cholesterol, according to the charity Heart UK - and Sliced Bread listener Cathy is one of them. She found out after taking a test at her GP and wants to do something about it. Her first plan of action is to make changes to her lifestyle, such as diet and exercise. As part of that, Cathy wants to know if the spreads and drinks that claim to lower cholesterol really do work.

Greg Foot is joined by Cathy and a panel of experts at our studios in Salford to investigate. What are the ingredients that are proven to lower cholesterol? How effective are they compared to widely-prescribed statins - and are the supermarket own brand versions of these drinks and spreads just as good as branded ones?

Milliy Universiteti Fizika fakultetida 2-yil dars berdim. Dars berish davomida salohiyatli kadrlarni tanlab loyihalarga (Center for Advanced Technologies - CAT Ilg'or texnologiyalar markazi - ITM) ishga oldim. 2 yil davomida yaxshi ishlashdi va 4 kursni tamomlagan bakalavrlarimiz Javokhir Khursandov, Rasul Mashalov hamda magistr talabamiz Muhriddindan Q1 jurnalda maqolamiz bugun online paydo bo’ldi. Shogirdlarimiz baraka topsin astoydil harakat qilishyapti. Maqolada ishtirok etgan hamkasblar Avez Sharipov hamda Farxod Turgunboyevga o'z minnatdorchiligimni bildiraman. Maqola haqida ma'lumot:
🧠🌟 Parkinson kasalligi (PD) - bu hozirda to'liq va aniq davolash strategiyalari yetishmayotgan neyrodejenerativ kasalliklar toifasi. PDning kelib chiqishi α-sinuklein deb nomlanuvchi peptidlarni aggregatsiyasi bilan bog’liq. Tashqi elektrostatik maydon qo'llanishi natijasida tolali strukturalarning peptidlarga ajralishi mumkinligi kuzatildi 🧬💡
Ushbu hodisani tushunish uchun biz molekulyar dinamika (MD) simulyatsiya usullaridan foydalanib, 0.1 V/nm elektr maydoni ta'sirida α-sinuklein peptidlarini o'rganib chiqdik. 🔬⚡️ MD simulyatsiyalari natijalari shuni ko'rsatdiki, tashqi elektr maydoni ta'sirida α-sinuklein monomer va oligomerik shakllari sezilarli konformatsion o'zgarishlarga uchrab, ularning qayta yig'ilishiga to'sqinlik qiladi. Biroq, model tizimdagi peptid birliklari soni oshgan sari, trimer va tetramerlar hosil bo'lganida, elektr maydoniga nisbatan barqarorlik ham oshadi. 🔄🔬
Bizning natijalarimiz shuni ko'rsatadiki, erta tashxis bilan PD rivojlanishini oldini olishda muhim bo'lishi mumkin. α-sinuklein asosan monomer yoki dimer shaklida mavjud bo'lganida, hatto elektr maydoni kichik qiymatlarini qo'llash ham dastlabki yig'ilish jarayonini samarali ravishda buzishi mumkin. ⏳🔍
α-sinuklein fibril shakllanishini erta bosqichlarda to'xtatish PDni kuchayib borayotgan va patogen α-sinuklein fibrillarining hosil bo'lishini to'xtatish orqali kurashishning samarali yechimi bo'lishi mumkin. 🌟🧬🛡

α-sinuklein fibril shakllanishini erta bosqichlarda to'xtatish PDni kuchayib borayotgan va patogen α-sinuklein fibrillarining hosil bo'lishini to'xtatish orqali kurashishning samarali yechimi bo'lishi mumkin. 🌟🧬🛡 https://www.sciencedirect.com/science/article/abs/pii/S1047847724000492
#ParkinsonsDisease #NeurodegenerativeDisorders #MolecularDynamics #Research #AlphaSynuclein #ElectricField #EarlyIntervention #ScientificDiscovery #HealthInnovation #BiomedicalResearch

Memorandum of Understanding (MoU) Signed Between IFAR and CAT

We are pleased to announce that the Institute of Fundamental and Applied Research (IFAR) at the National Research University TIIAME, represented by its Director, Dr. Jamoliddin Razzokov, has signed a Memorandum of Understanding (MoU) with the Center for Advanced Technologies (CAT) under the Ministry of Higher Education, Science and Innovation, represented by its deputy Director, Dr. Dilbar Dalimova.

This MoU marks the beginning of a collaborative partnership aimed at advancing research in several critical areas, including:

- Plasma Medicine: Leveraging non-thermal plasma (NTP) for cancer treatment through a combination of computer simulations and experimental studies to understand its selective effects on cancer cells.
- Neurological Diseases: Addressing the complexities of diseases such as Parkinson's and Alzheimer's by exploring the impact of electric fields and drugs on amyloid fibers using a blend of in-vitro experiments and computer simulations.
- Artificial Intelligence: Utilizing AI to identify peptide-based inhibitors for proteins involved in various diseases.
- Chronic Wound Healing: Investigating the potential of NTP to accelerate wound healing through combined in-vivo and in-silico studies.

Both IFAR and CAT are committed to sharing resources, expertise, and information to achieve these objectives, with plans for regular meetings, joint publications, and presentations at scientific conferences. This collaboration aims to develop innovative solutions and standards for medical treatments, benefiting the scientific community and patients alike.

We look forward to the groundbreaking research and advancements that will emerge from this partnership over the next five years.